Therapeutic effect and safety of ustekinumab for plaque psoriasis: A meta-analysis

Chinese Medical Sciences Journal

Volumn 29, Issue 3, 2014, Pages 131-138

  Liu, Yi ^a   Gong, Jian Ping ^b   Li, Wen Fang ^b  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

meta analysis; plaque psoriasis; ustekinumab

Indexed keywords

USTEKINUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; PSORIASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84908089711     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1001-9294(14)60057-2     Document Type: Article

References (14)

1. N Caca Biljanovska, M V'lckova Laskoska Principles of biological therapy in psoriasis Prilozi 34 2013 143 153
2. AJ Hueber, IB McInnes Immune regulation in psoriasis and psoriatic arthritis - recent developments Immunol Lett 114 2007 59 65
3. Y Wada, I Cardinale, A Khatcherian et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis PLoS One 7 2012 e35069
4. A Mason, J Mason, M Cork et al. Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review J Am Acad Dermatol 69 2013 799 807
5. A Kavanaugh, A Menter, A Mendelsohn et al. Effect of ustekinumab on physical function and healthy-related quality of life in patients with psoriatic arthritis: A randomized, placebo controlled, phase II trial Curr Med Res Opin 26 2010 2385 2392
6. N Kumar, K Narang, BD Cressey et al. Long-term safety of ustekinumab for psoriasis Expert Opin Drug Saf 12 2013 757 765
7. A Igarashi, T Kato, M Kato et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial J Dermatol 39 2012 242 252
8. R Parisi, DP Symmons, CE Griffiths et al. Global epidemiology of psoriasis: A systematic review of incidence and prevalence J Invest Dermatol 133 2013 377 385
9. S Dogra, R Mahajan Systemic methotrexate therapy for psoriasis: Past, present and future Clin Exp Dermatol 38 2013 573 588
10. GG Krueger, RG Langley, C Leonardi et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis N Engl J Med 356 2007 580 592
11. CL Leonardi, AB Kimball, KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
12. KA Papp, RG Langley, M Lebwohl et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
13. TF Tsai, JC Ho, M Song et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo- controlled trial in Taiwanese and Korean patients (PEARL) J Dermatol Sci 63 2011 154 163
14. X Zhu, M Zheng, M Song et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS) J Drugs Dermatol 12 2013 166 174